Rockefeller Capital Management
UNCY icon

Rockefeller Capital Management’s Unicycive Therapeutics UNCY Stock Holding History

Rockefeller Capital Management’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.5K Buy
1,600
+1,100
+220% +$7.21K ﹤0.01% 3971
2025
Q4 		$2.88K Hold
500
– – ﹤0.01% 4232
2025
Q3 		$2.18K Buy
+500
New +$2.18K ﹤0.01% 4074

Other funds holding UNCY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rockefeller Capital Management's UNCY Position: Q1 2026 in Review

Rockefeller Capital Management increased its Unicycive Therapeutics (UNCY) stake by 220% in Q1 2026, buying an estimated $7.21K and bringing the position to 1,600 shares worth $10.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3971.

Rockefeller Capital Management first reported a position in UNCY in Q3 2025 and has held it in 3 quarters since. 51 funds tracked by Wall St. Rank hold UNCY as of Q1 2026.

  • Rockefeller Capital Management held 1,600 shares of Unicycive Therapeutics worth $10.5K as of Q1 2026.
  • Rockefeller Capital Management bought 1,100 Unicycive Therapeutics shares in Q1 2026, an estimated $7.21K.
  • Unicycive Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #3971 holding.
  • Rockefeller Capital Management first reported a position in Unicycive Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 51 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.